Tag:
Repligen
Latest Headlines
Latest Headlines
Repligen shares tank on expected FDA rejection
Repligen put out the word this morning that the FDA has cancelled an expert panel review of its pancreatic imaging agent.
NINDS is close to launching its first NeuroNEXT neurobiomarkers study
The National Institute for Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), is getting ready to launch the first of the studies through NeuroNEXT, the
Repligen snags Novozymes business in $28.3M deal
Repligen has made a move to boost its biomanufacturing capacity and its commercial prospects. The Waltham, MA-based biotech says it grabbed Novozymes Biopharma Sweden for $22.7 million (€17
Biomarker study to aid clinical trial of spinal muscular atrophy drug
In companion research to go along with the first-ever clinical trial of a drug to treat spinal muscular atrophy, the Jasper Clinic in Kalamazoo, MI, is recruiting patients for a clinical study that
Repligen gets fast tracked for spinal muscular atrophy
Waltham, MA-based biotech Repligen has received FDA fast-track designation for its spinal muscular atrophy treatment, RG3039. The drug also received orphan drug status from the EMA. Repligen is
Repligen shares tank after depression drug flunks a Ph2b
Shares of Repligen ( $RGEN ) dived 28 percent yesterday after the Waltham, MA-based biotech said the Phase IIb study of RG2417--an oral formulation of uridine--failed to reflect a statistically
Repligen imaging agent fails Phase III primary endpoint
A late-stage trial of Repligen's RG1068--a pancreatic imaging agent--missed its primary endpoint, pushing the company's stock down 15 percent this morning. In spite of the results, the developer
BMS, Repligen settle Orencia fight
Four companies, two disputed patents, two multimillion-dollar settlements. Repligen and Bristol-Myers Squibb buried the hatchet over Orencia, the rheumatoid arthritis treatment that's been subject
Erbitux clears late-stage hurdle for lung cancer
ImClone once again is feeling the tonic effects of positive trial data. Its stock price took off this morning, rising 19 percent after its European partner, Merck KGaA, reported that Erbitux helped
